Hill February 17, 2024
The Food and Drug Administration (FDA) announced Friday that it approved a ground breaking cellular therapy treatment for patients with advanced melanoma, and surgery has been unsuccessful.
Amtagvi, a type of T-cell therapy, involves boosting immune cells within tumor tissue to help the body fight off the cancer. During the treatment, the patient’s t-cells are separated from the tumor, artificially multiplied and then returned to them via infusion, the FDA said in a press release.
“Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal,” said Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research (CBER), said in a press release. “The approval of Amtagvi represents the culmination of scientific and clinical...
Today's Sponsors
Today's Sponsor